Biologics Used for Psoriasis: A Drug Utilization Study Based on Two Nationwide Danish Data Sources
Adalimumab, ustekinumab, and secukinumab were the most common first-choice treatments in Denmark. Overall, ustekinumab showed the longest drug survival. We observed important differences in treatment cascades and drug survival between Dermbio and the healthcare registries, which should be considered when using these data sources to perform drug utilization studies on biologics.
Authors
- Alexander Egeberg (ORCID: https://orcid.org/0000-0001-8257-1816)
- Mette Reilev (ORCID: https://orcid.org/0000-0003-1241-4385)
- Jesper Hallas (ORCID: https://orcid.org/0000-0002-8097-8708)
- Peter Jensen (ORCID: https://orcid.org/0000-0003-4887-1721)
- Nanna Philbert Engel‐Andreasen (ORCID: https://orcid.org/0009-0008-8613-5892)
Institutions
- University of Copenhagen (DK)
- University of Southern Denmark (DK)
- Bispebjerg Hospital (DK)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1002/pds.70050
- Citations
- 4
- Primary Topic
- Historical Medical Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.62
Funders
- Syddansk Universitet